Clearmind shares surge 16.96% premarket after positive AUD trial data, DSMB approval, and Israel site expansion.

Clearmind Medicine Inc. surged 16.96% in premarket trading following three key developments in its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral therapy targeting Alcohol Use Disorder. The company reported positive top-line results from the first cohort of six participants at elite sites including Johns Hopkins and Yale, followed by unanimous approval from the independent Data and Safety Monitoring Board (DSMB) to continue the trial. Additionally, enrollment commenced at Tel Aviv Sourasky Medical Center in Israel, expanding the multinational study’s recruitment capacity. These milestones underscore progress in Clearmind’s FDA-approved trial, enhancing investor confidence in the therapy’s safety and potential efficacy amid a $249 billion annual market need for AUD treatments. The DSMB’s endorsement and site expansion are critical catalysts for accelerating clinical data collection and future phases.